; WALL STREET CHOICE: VYTORIN/ZETIA DAMAGE IS NOT AS BAD AS FEARED
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

WALL STREET CHOICE: VYTORIN/ZETIA DAMAGE IS NOT AS BAD AS FEARED

VIEWS: 3 PAGES: 1

In the first five days following the ACC panel in late March, Vytorin and Zetia new prescription market share declined a respective 135 basis points and 74 basis points compared to 175 drop in new prescriptions Vytorin and 156 for Zetia in the first five days following January 14, when the data were disclosed. Furthermore, in the last round, the majority of market share losses occurred in the first week. More thought leaders have stepped forward in support of Vytorin and Zetia.

More Info
To top